Beta cell function and mass in individuals with and without remission of type 2 diabetes after Roux-en-Y gastric bypass
Authors' conclusion
Individuals with remission of type 2 diabetes after RYGB have better beta cell function than those not achieving remission, but the groups did not differ with respect to beta cell mass. Our preliminary data argue against a stimulating effect of RYGB on beta cell mass, although revival of non-functional (so-called dormant) beta cells is a possible explanation for remission.
Study context
- Population
- Individuals with T2D and obesity after RYGB
- Participants
- 8 vs 9
- Comparison
- Remission vs no remission of T2D after RYGB
- Remissionn = 8
- No remissionn = 9reference
- Outcome
- Beta cell mass measured by [68Ga]Ga-NODAGA-exendin-4 PET/CT
Methodological details[68Ga]Ga-NODAGA-exendin-4 PET/CT imaging
- [68Ga]Ga-NODAGA-exendin-4 PET/CT imaging
Main finding
As reported in the abstract
Beta cell mass
P = 0.87
Further findings
Beta cell function, ARGT (AUC C-peptide/fasting glucose) · after RYGB · higher with Remission
P = 0.001
Median
| Outcome | Remission | No remission | P value |
|---|---|---|---|
| Beta cell function, OGTT (AUC C-peptide:AUC glucose) · after RYGBHigher with Remission | 0.15 (IQR 0.11–0.24) | 0.032 (IQR 0.023–0.054) | P = 0.005 |
HOMA2-%B
- Better in remission group and significantly improved after RYGB; unchanged in non-remitters
Diabetes duration
- Shorter diabetes duration with remission than without
Original publication
Beta cell function and mass in individuals with and without remission of type 2 diabetes after Roux-en-Y gastric bypass. Diabetologia. Published 20 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →